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Abstract Extracellular nucleotides are ubiquitous signal-
ling molecules, acting via the P2 class of surface receptors.
Platelets express three P2 receptor subtypes, ADP-
dependent P2Y1 and P2Y12 G-protein-coupled receptors
and the ATP-gated P2X1 non-selective cation channel.
Platelet P2X1 receptors can generate significant increases in
intracellular Ca
2+, leading to shape change, movement of
secretory granules and low levels of αIIbβ3 integrin
activation. P2X1 can also synergise with several other
receptors to amplify signalling and functional events in the
platelet. In particular, activation of P2X1 receptors by ATP
released from dense granules amplifies the aggregation
responses to low levels of the major agonists, collagen and
thrombin. In vivo studies using transgenic murine models
show that P2X1 receptors amplify localised thrombosis
following damage of small arteries and arterioles and also
contribute to thromboembolism induced by intravenous co-
injection of collagen and adrenaline. In vitro, under flow
conditions, P2X1 receptors contribute more to aggregate
formation on collagen-coated surfaces as the shear rate is
increased, which may explain their greater contribution to
localised thrombosis in arterioles compared to venules
within in vivo models. Since shear increases substantially
near sites of stenosis, anti-P2X1 therapy represents a
potential means of reducing thrombotic events at athero-
sclerotic plaques.
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Introduction
In addition to its role as an energy source, ATP is an
important extracellular signalling molecule, acting via the
P2 family of surface receptors. These membrane-spanning
proteins are divided into P2X receptors, which are ligand-
gated non-selective cation channels, and P2Y receptors,
which couple to signalling pathways principally through
heterotrimeric G-proteins. The platelet is known to express
three P2 receptor subtypes, P2X1, P2Y1 and P2Y12.
Although ATP can activate P2Y1 and P2Y12 receptors
when expressed at high density [1–3], it is a weak, partial
agonist and unable to generate G-protein-coupled receptor
(GPCR)-evoked responses in the platelet due to the low
levels of P2Y receptor expression [4–6]. Therefore, the
large amounts of ATP released from cells following
vascular injury will directly stimulate platelet responses
only through P2X1 receptors. Work from a number of
laboratories, both in vivo and in vitro, has demonstrated a
widespreadability for P2X1-evokedCa
2+ influx to contribute
to platelet function. In this review, we discuss the biophysical
properties of P2X1 and their signalling mechanisms. We also
examine the evidence that this ligand-gated ion channel
influences platelet function, both alone and in tandem with
other receptor pathways. Finally, we discuss how platelet
P2X1 receptors are activated in the circulation in health and
disease, and thus when their inhibition could result in
greatest therapeutic benefit.
Biophysical properties and regulation of P2X1 receptors
Seven P2X receptor subunit isoforms have been identified,
classified as P2X1 to P2X7 by their chronological order of
discovery [7, 8]. They comprise a novel family of ligand-
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brane domains, intracellular amino and carboxy termini and
a large extracellular ligand-binding loop. P2X channels
form as either homotrimers or heterotrimers, which vary in
their kinetics of desensitisation and pharmacology, although
all are activated by the physiological ligand ATP [9]. The
publication of a crystal structure for the zebra fish P2X4
receptor in an agonist-free state was a major advance in the
understanding of the structural basis of P2X receptor
properties [10]. The structure confirmed the predicted
trimeric nature of the receptor and that the second
transmembrane domain lines the ion conducting pore [11–
13]. Mutagenesis has identified a role for conserved amino
acids in ligand action at P2X receptors and mapping of the
crystal structure shows that these residues are clustered at
the interface between two adjacent receptor subunits,
consistent with pre-crystalisation predictions [14–16]. The
phosphate tail of ATP has been predicted to be co-ordinated
by three lysine residues (K68 and K70 from one subunit
and K309 from the adjacent subunit, P2X1 receptor
numbering) with the adenine ring bound to a conserved
NFR motif (290–292 on the same subunit as K309, P2X1
receptor numbering) deeper within the binding groove
formed between the subunits [16]. This mode of ATP
binding places the terminal phosphate facing out towards
the surface of the receptor. This orientation also allows
additional groups to be accommodated onto the terminal
phosphate, consistent with the agonist action of dinucleotide
polyphosphates (see later). Residues associated with sensitiv-
ity to the antagonists suramin and PPADs are also located
around the predicted ATP binding pocket [10, 16].
P2X1 receptor subunits can form homomeric ion
channels, but can also interact with other P2X subunits, e.g.
P2X5, to form heteromeric ion channels with distinct
properties [17, 18]. However, degenerate P2X primers
detected only P2X1 mRNA in human platelets and related
cell lines [19], and a quantitative PCR screen of all P2X
receptors in highly purified human platelets found only
P2X1 at significant levels [20]. Moreover, murine mega-
karyocytes from P2X1-deficient mice show no ATP-gated
P2X currents in whole-cell patch clamp recordings [21].
Thus, only homomeric P2X1 receptors form ATP-gated ion
channels in the platelet and megakaryocyte.
P2X1 receptors show appreciable permeability to Ca
2+
(the relative permeability of Ca
2+ compared to Na
+, i.e.
PCa/PNa, is 3.9) [22, 23] and under physiological con-
ditions ≈10% of current flow through the receptor is
mediated by Ca
2+ [24, 25]. These ion channels can
therefore provide a significant source of direct Ca
2+ influx
into the cell following activation, as well as causing
membrane depolarization that has been demonstrated to
enhance signalling through P2Y1 and other Gq-coupled
receptors [26, 27]. The time course of ATP-evoked P2X1
receptor-mediated currents is concentration-dependent with
low concentrations (e.g. <100 nM, see [28]) taking several
seconds to reach a peak response, which can be sustained
for >30 s. This property may contribute to the ability of
P2X1 to sustain Ca
2+ signals following ATP secretion
during stimulation by key platelet agonists [29]. In contrast,
at maximal agonist concentrations, P2X1 receptor currents
peak within tens of milliseconds and desensitise completely
within seconds [28, 30, 31].
P2X1 receptor-mediated currents can be potentiated
following the activation of Gαq-coupled GPCRs (GqPCRs)
in a protein kinase C-dependent manner [32, 33]. This
regulation is thought to occur through the phosphorylation
of a protein that interacts with the intracellular amino
terminus of the receptor [34]. Amongst the GqPCRs shown
to potentiate P2X1 receptor currents in recombinant
systems are P2Y receptors [32], suggesting that platelet
P2Y1 receptor activation may sensitize subsequent responses
to ATP. A second regulatory mechanism for P2X1 receptors
is their association with cholesterol-rich lipid rafts [35]t h a t
could act to establish a pre-formed signalling complex in the
cells. In both recombinant systems and platelets, disruption
of lipid rafts results in >80% reduction in the amplitude of
P2X1 receptor responses [35, 36]. In platelets, >80% of
P2X1 receptors reside outside lipid rafts [36], raising the
possibility that these constitute a reserve pool of receptors
that can become active on recruitment into the rafts. These
studies also raise the possibility that platelet P2X1 responses
may be modulated by diet or by cholesterol-lowering statins.
Finally, trafficking of P2X1 receptors can play an important
role in their regulation. Recent studies have shown that green
fluorescence protein-tagged P2X1 receptors are highly
mobile in the membrane with movement of ≈75% of
receptors into/out of a given area of membrane within
5m i n[ 37]. This work has also shown that following
receptor activation, internalization and recycling plays a key
role in recovery of responses from desensitisation [37].
P2X1 receptor-mediated currents are therefore subject to
regulation by a range of mechanisms giving rise to the
ability to fine-tune P2X1 receptor functional responsiveness
in platelets.
Desensitisation and recovery of P2X1 activity
In order to study P2X1 receptor function in platelets in
vitro, it is essential to reduce the desensitisation that occurs
due to spontaneously secreted ATP [38]. To achieve this,
most studies have used apyrase (EC 3.6.1.5) derived from
potato, which has both ADPase and ATPase activity. A
higher apyrase concentration is required to protect P2X1
receptors from desensitisation compared to that needed to
limit P2Y1 receptor desensitisation; ≈0.3–1 U/ml apyrase is
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receptors to function with negligible P2X1 responses [29,
38–42]. Further increases to 5 U/ml have been shown to
amplify α,β-meATP-evoked shape change [43]; however,
even in the presence of high apyrase levels, P2X1 activity
still declines [38, 44], either due to insufficient speed of
apyrase action or release of non-metabolised nucleotide
polyphosphates. This raises the possibility that in vitro
studies have underestimated the maximal effects of P2X1
receptors on platelet function. P2X1 receptor currents in
human platelets and mouse megakaryocytes [31, 45]( i n
studies where the active agonist ATP was added as a
contaminant in commercial samples of ADP) recover almost
completely from an agonist-induced desensitised state over a
period of ≈5 min. Platelet P2X1 receptor activity in plasma
also shows recovery from a desensitised state due to
endogenous ectonucleotidases [46]. Thus, in an in vivo
environment where platelets are surrounded by substantial
ectonucleotidase activity [47, 48], platelet P2X1 receptors
will be expected to recover from activation within minutes
after degradation of agonist and be available for stimulation
multiple times during the lifespan of a platelet.
Tools to activate and inhibit P2X1 function
ATP is the physiological agonist at P2X1 receptors; however,
the hydrolysis-resistant analogues α,β-methyleneATP (α,β-
meATP) and β,γ-methylene ATP (β,γ-meATP) are common-
ly used to activate platelet P2X1 responses due to the
requirement for ectonucleotidase activity to prevent desensi-
tisation. α,β-meATP displays a similar potency to ATP (EC50
of ≈1 μM), although some studies show it is a partial agonist
in expression systems (maximal response ≈60–70% of that
observed with ATP [28] (Allsop and Evans, unpublished
observations). β,γ-meATP has been used preferentially in
some studies of platelet P2X1 receptors [49], as a conse-
quence of its >30-fold selectivity for P2X1 over P2X3
receptors, in contrast to the similar EC50 for α,β-meATP at
these two desensitising P2X receptors [49, 50]. However,
β,γ-meATP is far less potent at P2X1 receptors, with a
maximal response ≈40% of that observed with ATP and
displaying a 10-fold higher EC50 [50]. Thus, it is possible
that the maximal contribution of P2X1 receptors to platelet
function may have been underestimated in some studies
using non-hydrolyseable analogues.
Despite the availability of high affinity P2X1 antagonists
based on suramin and PPADS [51–53], caution must still be
taken to achieve selective inhibition of P2X1 without also
affecting P2Y receptors, particularly P2Y1 [29, 41, 42, 54].
A further complication is the significantly lower potency of
these antagonists at P2X1 receptors in native compared to
recombinant systems [29, 41, 42, 51–57]. In human platelets,
the suramin derivative NF449 shows good (≈72-fold) ability
to discriminate between P2X1 and P2Y1 receptors, and only
starts to influence P2Y12 receptors at very high concen-
trations [42, 54]. Thus, 0.3–1 μM NF449 has been used to
achieve almost complete block of human P2X1-evoked
responses with no observable reduction in P2Y-mediated
effects [29, 41, 42, 54]. In contrast, MRS 2159 shows far
less ability to discriminate between platelet P2X1 and P2Y1
receptors, with only a 6-fold difference in potency at Ca
2+
responses [29, 54], thus selective block of P2X1 responses
with this compound is difficult. Other P2X1 antagonists used
in platelet studies are the PPADS derivative PPNDS [58]a n d
the suramin derivative NF279 [59, 60]; however, their ability
to discriminate between P2 receptors in the platelet has not
been fully examined and non-specific actions have been
described, including block of ectonucleotidases for NF279
[61] and modulation of AMPA receptors (which also exist in
platelets [62]) for PPNDS [63]. ADP is not an agonist at
P2X1 receptors [64] and has been used by one group to
block α,β-meATP-evoked platelet P2X1 responses at equi-
molar concentrations [43, 65]. However, this antagonism has
not been reported by other groups and is at odds with early
patch clamp studies using commercial ADP samples, where
an estimated 0.5–1 μM ATP could activate human platelet
P2X1 receptors in the presence of ≈50-fold higher ADP
concentrations [31]. One established approach to selectively
abolish P2X1 activity is to desensitise the receptor with α,β-
meATP or β,γ-meATP, particularly if this can be achieved
prior to addition of external Ca
2+, thereby avoiding
functional responses [29, 38]. α,β-meATP is far preferable
as a desensitising agent since it is without effect on P2Y1
receptor-evoked Ca
2+ increases, compared to weak compet-
itive inhibition by β,γ-meATP [5, 66, 67].
Functional effects of platelet P2X1 receptor activation
reported in vitro
Effects of selective P2X1 receptor activation It is likely that
desensitisation by spontaneously released nucleotides
accounts for the lack of P2X1-dependent functional
responses reported by early in vitro studies [68–70].
Selective activation of P2X1 receptors is now known to
stimulate a rapid and reversible shape change, peaking
within a few seconds and returning to a resting state after
≈1 to 2 min [38, 43, 71, 72] (see Fig. 1a). This receptor also
stimulates transient granule centralization and low levels of
inside-out activation of αIIbβ3 integrin leading to weak,
transient aggregation [39, 73]. Quantification of scanning
electron micrographs [72] indicated that only 40% of
platelets altered their shape in salines with 1 mM Ca
2+ in
response to a maximal α,β-meATP concentration; however,
it is likely that all platelets possess functional P2X1
Purinergic Signalling (2011) 7:341–356 343receptors since increasing Ca
2+ entry by elevating external
Ca
2+ induced a shape change in virtually all platelets [72].
Nevertheless, this does imply an inter-platelet heterogeneity
either in the amplitude of the P2X1 response in vivo or the
speed of desensitisation in vitro. Evidence for both
mechanisms exists. For example, Wang et al. [20] show a
far greater mRNA degradation rate in vitro of P2X1
compared to P2Y1 and P2Y12 receptors and, given reports
that platelet mRNA is transcriptionally active [74], suggest
that P2X1 receptor levels may decrease with the age of the
platelet. We have also observed a significant inter-donor
variability in the rate at which P2X1 receptor Ca
2+ responses
decline in vitro, with between 0% and >90% of the response
to 10 μM α,β-meATP remaining after 1 h [38, 44].
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Fig. 1 Effects of P2X1 receptors on platelet activation studied in
vitro. a Reversible shape change of human platelets following
selective activation of P2X1 receptors with α,β-meATP. Scanning
electron micrographs of washed platelets before stimulation (i), or 10 s
(ii) and 60 s (iii) after addition of 10 μM α,β-meATP in the presence
of 1 mM extracellular Ca
2+. b Contribution of P2X1 receptors to
aggregation at different collagen concentrations demonstrated using
platelets from wild-type (black traces) and P2X1-deficient (grey
traces) mice. c Enhancement of PAR1-dependent aggregation in
human platelets by P2X1 receptor activation. The amplification of
TRAP1 (SFLLRN)-induced aggregation is reduced as the time
between P2X1 stimulation with α,β-meATP (1 μM) and TRAP
(SFLLRN, threshold concentration) is increased from 0.25 to 3 min;
additions at 15 s and 1 min are shown by the arrow heads, while the
addition at 3 min is not shown. Figures reproduced from [38, 40, 71],
with permission. The vertical axes in b and c have units of % light
transmission; an upward deflection represents an increase in trans-
mission and thus an aggregation. Traces in c have been inverted from
the original reference to be consistent with those in b
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greatest influence of P2X1 receptors on platelet function
reported during in vitro studies with stirred platelet-rich
plasma (PRP) or washed suspensions is an enhancement of
aggregation mediated by low to intermediate (0.5–
1.25 μgm l
−1) concentrations of collagen [43, 71, 75]
(Fig. 1b). This may be a consequence of the significant
contribution of P2X1 receptors to intracellular Ca
2+
responses (up to 90% of the peak) generated by low
concentrations of collagen [29, 76]. P2X1 receptors also
enhance dense granule secretion responses to collagen [71],
although whether this contributes to, or is a consequence of,
the increased aggregation has not been investigated. At
higher collagen concentrations (2.5 μgm l
−1), P2X1 has no
essential involvement in the aggregation response (Fig.1b).
In studies of stirred platelets, collagen stimulates ATP
release and thus P2X1 activation through the glycoprotein
VI receptor, since the effects can be mimicked by
stimulation of human platelets with collagen-related peptide
or stimulation of P2X1 over-expressing platelets with the
snake venom convulxin [29, 75].
The role of P2X1 receptors in collagen-evoked platelet
activation has also been studied under conditions of flow,
where blood is perfused through a narrow chamber across a
surface coated with collagen. The flow rate (and in some
cases, the chamber lumen) is varied to mimic the wall shear
rates experienced by blood cells in different parts of the
circulation. Studies with blood from P2X1
−/− mice show
little role for this receptor at a shear rate of 800 s
−1, but that
it amplifies thrombus formation on the collagen surface as
the shear is increased, becoming highly significant at levels
experienced in small arteries and arterioles (6,000 s
−1)[ 71].
Over-expression of P2X1 also allows this receptor to
contribute to aggregate formation and phosphatidylserine
exposure when the platelets are perfused over a collagen
surface at low shear (1,000 s
−1)[ 75].
RoleofP2X1receptorsduringactivationbythrombin Hechler
and colleagues [41, 71] observed no significant role for
P2X1 receptors in protease-activated receptor (PAR)-
evoked aggregation for either murine or human platelets
stimulated by thrombin or human platelets stimulated by
PAR1 thrombin receptor activating peptide (TRAP1). Over-
expression of P2X1 in murine platelets also had no
detectable effect on thrombin-evoked aggregation [75]. In
contrast, in a study by Erhardt et al. [40], P2X1 sub-
stantially amplifies aggregation induced by TRAP4 in
murine platelets or TRAP1 in human platelets. P2X1
contributes only at threshold concentrations of the peptides,
which for humans varied between donors, thus it is possible
that the thrombin or TRAP1 levels used in the work of
Hechler et al. [41, 71] and Oury et al. [75] represent a
supra-threshold stimulus. In support of this explanation,
secondary activation of P2X1 has been shown to amplify
thrombin-evoked Ca
2+ increases mainly at low to medium
thrombin concentrations [29]. Erhardt et al. [40]a l s o
observed synergy between P2X1 and PAR1 when α,β-
meATP was added prior to TRAP1 in human platelets [40].
As expected from the transient time course of P2X1-evoked
Ca
2+ and cytoskeletal responses, the synergy decreased as
the interval between addition of α,β-meATP and TRAP1
was increased, although was still detectable for up to 3 min
(see Fig. 1c). This effect could be important in the context
of thrombus formation since release of ATP from damaged
cells will stimulate P2X1 receptors very quickly following
vascular injury compared to the generation of thrombin
[77]. Grenegard et al. [78] have also observed small levels
of aggregation induced by α,β-meATP after a subthreshold
thrombin concentration.
Interactions between P2X1 and adrenaline receptor path-
ways Adrenaline activates platelets via α2A receptors
which, like P2Y12 receptors, couple through the Gi family
of G-proteins and strongly synergise with Gq-coupled
receptors to stimulate aggregation [79–84]. Activation of
P2X1 receptors in hirudinated PRP synergizes with
subthreshold concentrations of adrenaline to generate small,
but significant levels of aggregation [39]. Surprisingly, this
synergy was not observed between P2Y12 and P2X1
receptors [72], which may result from different Gαi-
coupled pathways downstream of P2Y12 compared to
α2A [85–89], or the fact that the P2Y12 study was
conducted in washed platelets since adrenaline displays a
greater ability to stimulate aggregation in plasma compared
to washed suspensions [79–84]. In a study of synergy
between PAR and α2A receptors in aspirin-treated human
platelets, both MRS 2159 and NF449 (P2X1 antagonists),
but not MRS 2179 or cangrelor (P2Y1 and P2Y12
antagonists, respectively), abolish the aggregation that
results when adrenaline is added after subthreshold con-
centrations of thrombin, suggesting a major role for ATP
secretion and activation of P2X1 receptors [78].
Role of P2X1 receptors during activation by thromboxane
A2 In human platelets, [Ca
2+]i increases stimulated by low-
intermediate (0.5–1 μM) concentrations of the stable
thromboxane A2 analogue, U46619, are enhanced by
release of ATP and secondary activation of P2X1 receptors
[29]. However, no amplification of thromboxane A2-
evoked aggregation was observed by one group in human
or murine platelets at a slightly higher concentration of
U46619 (2–2.5 μM), which induced secretion of nucleo-
tides from dense granules [41, 71]. Human P2X1 receptor
over-expression in murine platelets markedly amplifies
U46619-induced aggregation at 1–1.75 μM U46619,
although surprisingly the synergy was not observed at only
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[75]. Thus, the apparent discrepancy between different
reports may result either from varying P2X1 receptor
response magnitudes or a role for P2X1 over only a narrow
concentration range of U46619. The underlying mechanism
for the synergy may involve P2Y receptor stimulation since
P2X1 can enhance U46619-induced dense granule secre-
tion [75].
P2X1:P2Y receptor interactions To study interactions
between P2Y and P2X1 receptors, the ADP used to
stimulate P2Y1 and P2Y12 receptors must be purified by
HPLC or treated with hexokinase in the presence of glucose
to remove the small but significant contaminating levels of
ATP [31, 64, 90–94]. The level of ATP contamination can
be easily determined using a luciferin–luciferase assay [29].
Despite the fact that P2Y receptors induce only a weak
secretion response, secondary activation of P2X1 receptors
by secreted ATP can significantly enhance the peak Ca
2+
increase, albeit briefly compared to the effect after collagen
and thrombin stimulation [29]. This amplification varies
between donors, which may be due to natural variations
known to exist in the amplitude of P2Y receptor responses
[95, 96] and/or variable P2X1 responses (see earlier). The
consequence of this P2Y-evoked ATP release and P2X1
activation is unclear,sincedeletion,pharmacologicalblockor
upregulation of P2X1 in murine platelets has no effect on
ADP-evoked aggregation [41, 71, 75, 96]. ATP and ADP are
both released from dense granules, therefore, it is more
relevant to consider the consequences of co-stimulation of
P2X1 and P2Y receptors. Thus, it is interesting to note that
co-addition of α,β-meATP and purified ADP accelerates and
enhances the peak Ca
2+ response compared to that expected
for summation of individual responses [21]. In the arterial
circulation, platelets that initially attach to a damaged vessel
wall or ruptured plaque will be swept away unless
sufficiently activated within a narrow time-window. The
synergy between P2X1 and P2Y1 may increase the chances
of this occurring and thus contribute to the involvement of
P2X1 in arterial thrombosis.
Role of P2X1 during Toll receptor activation Platelets are
known to contribute to immune responses, particularly by
linking the innate and adaptive immune systems [97]. Toll-
like receptors (TLR) 1, 2, 4, 6 and 9 are expressed on
platelets and recognise a number of molecules derived from
microbes (e.g. lipopolysaccharide, peptidoglycan) [97–99].
A specific agonist of TLR2/1 receptors stimulates aggrega-
tion and secretion in human platelets that can reach
approximately 50% and 100%, respectively of those
induced by 1 μgm l
−1 collagen [100]. Of particular note,
TLR2/1-induces an intracellular Ca
2+ increase that is totally
blocked by 10 μM MRS 2159, and although this
concentration will start to inhibit P2Y1 receptors (see
above), MRS 2179 on its own had no effect [100]. P2X1
receptors can also contribute to TLR2/1-evoked functional
responses, since MRS 2159 reduced the aggregation
response to a TLR2/1-specific ligand by 50%. A low
concentration of MRS 2159 (1 μM) was used in this
experiment, thus the maximal contribution of P2X1 may be
greater. However, the relative importance of P2X1 as a
secondary receptor is unclear since antagonists of P2Y1,
P2Y12 and thromboxane A2 generation also have substantial
inhibitory effects on TLR2/1-dependent aggregation. Never-
theless, these data suggest that P2X1 may have a role in
immune responses, and thereby may play a role in the
development of atherosclerosis, a chronic inflammatory
disease. P2X1 responses have also been implicated in the
platelet antimicrobial responses to Staphylococcus aureus,
but based upon a high concentration (300 μM) of the less
well-characterized P2X1 receptor inhibitor PPNDS [101].
Role of P2X1 receptors in shear-induced platelet aggrega-
tion The relative contribution of different surface receptors
and agonists to platelet responses varies over the range of
shear levels experienced within the circulation (reviewed in
[102, 103]). As the shear rate increases, the adhesive ligand
von Willebrand Factor (vWF) plays an increasingly
important role in the tethering of platelets and subsequent
aggregation. vWF binds to both GPIb and αIIbβ3, although
these receptors directly generate only weak intracellular
signals, such that additional responses evoked by collagen
through GPVI and by soluble agonists are required for
sufficient activation of αIIbβ3 to form a secure thrombus
(reviewed in [102, 103]). The importance of P2X1 at high
shear has been studied by flow over collagen surfaces (see
above section). In addition, shear-induced platelet aggrega-
tion (SIPA) has been studied in a cone and plate viscometer,
at levels where aggregation is dependent upon the presence
of vWF and involves both GPIb and αIIbβ3 [41, 49]. The
shear stress used in these studies stimulates release of dense
granules, and the major role of released ADP and P2Y
receptors in the subsequent aggregation is well established
[104, 105]. In the study of Hechler et al. [41], addition of
0.5 U/ml apyrase increased SIPA, an effect antagonized by
low levels of NF449 or preincibation with α,β-meATP, thus
suggesting involvement of P2X1 receptors. In contrast,
Oury et al. [49] observed a reduced SIPA with the same
concentration of apyrase and MRS 2159 reduced SIPA even
in the absence of apyrase, therefore altered P2Y receptor
responses may be responsible for these effects. However,
their study does support a role for P2X1 receptors in
responses to shear since β,γ-meATP enhanced SIPA in
normal apyrase-treated platelets and was also able to induce
SIPA in platelets from a patient with an almost total absence
of granule secretion (Hermansky–Pudlak syndrome) [49].
346 Purinergic Signalling (2011) 7:341–356Other synergistic effects of P2X1 P2X1 receptors also show
mild synergy with the weak platelet agonist thrombopoie-
tin, resulting in enhanced aggregation, albeit still a minor
response [39]. The underlying mechanism is not known but
does not involve an enhancement of Ca
2+ mobilisation [39].
Platelets prepared using heparin as an anticoagulant also
show potentiated P2X1 receptor responses in plasma such
that α,β-meATP can induce significant aggregation
responses, compared to only shape change when hirudin
is the anticoagulant [39]. Again, the underlying mechanism
was not studied but it is well-known that heparin enhances
the activation of platelets in plasma in response to a number
of agonists [106, 107].
Signalling through the P2X1 receptor in the platelet
Activation of P2X1 receptors leads to influx of both Ca
2+
and Na
+ [30, 38, 71, 72, 93], and may also depolarize the
platelet membrane potential from its resting level of −50 to
−60 mV [108–110]. Although depolarization and increased
cytosolic Na
+ are putative contributors to signalling [26, 93,
111], all functional events reported to date following
activation of P2X1 receptors depend upon Ca
2+ influx
[38, 39, 71–73]. The Ca
2+ increase activates calmodulin-
dependent myosin light chain kinase (MLCK) resulting in
myosin light chain phosphorylation (MLC-P) and thereby
generating the cytoskeletal events that underlie shape
change and granule localization [38, 73]. P2X1 does not
stimulate shape change through Rho-kinase [73], the
pathway used dichotomously by certain receptors (e.g.
P2Y1) to generate cytoskeletal events [112–115]. Oury et
al. [65] also show that selective P2X1 activation causes
transient phosphorylation of ERK2, a member of the
mitogen-activated protein kinase family. Based upon
experiments with extracellular EGTA, the broad spectrum
PKC inhibitor GF109203-X and the calmodulin inhibitor
W-7, P2X1-evoked ERK2 phosphorylation requires extra-
cellular calcium and activation of both calmodulin and PKC
[65, 73]. However, P2X1-evoked ERK2 phosphorylation is
slow compared to the shape change, reaching maximal
phosphorylation at 2 min and disappearing after 10 min
[65]. Thus, not surprisingly, inhibition of ERK2 phosphor-
ylation with the MEK1/2 antagonist U0126 does not alter
αβ-meATP-evoked shape change [73]. The main role of
ERK2 activation by P2X1 is proposed to be the enhance-
ment of aggregation during low to intermediate levels of
collagen [65, 73, 75]. Following stimulation by ≤1 μgm l
−1
collagen, desensitisation of P2X1 reduces ERK2 phosphor-
ylation; furthermore, block of ERK2 phosphorylation with
U0126 impairs the aggregation and major dense granule
secretion at this low level of GPVI stimulation [43].
However, at high collagen concentrations, aggregation and
secretion do not depend upon P2X1 or ERK2 activation.
Collagen causes an early, minor dense granule secretion
that does not involve ERK2 and P2X1 activation, although
it has not been directly investigated how dependent the
subsequent P2X1-induced ERK2 phosphorylation is upon
this early ATP release [65]. Studies with transgenic mice
over-expressing the human P2X1 receptor in the megakar-
yocytic cell lineage support the involvement of ERK2 in
P2X1-induced potentiation of collagen responses [75].
ERK2 phosphorylation, secretion and aggregation in
response to threshold collagen concentrations are all
enhanced in platelets from these mice, and these increased
responses are all abolished by prior P2X1 desensitisation
[75]. A number of outstanding questions remain regarding
the role of the reported P2X1-induced ERK2 activation in
platelet function, including its relative importance in the
potentiation of responses to agonists other than collagen.
Furthermore, it is unclear why ADP (up to 20 μM) was not
able to activate ERK2 phosphorylation [65], since P2Y
receptors have been shown to generate Ca
2+ responses that
can exceed and outlast those generated by P2X1 receptors
in physiological salines [65, 72, 73].
The mechanisms by which P2X1 receptors contribute to
SIPA appear to be distinct from those involved in amplifi-
cation of the collagen responses. Oury et al. [49]d e m o n -
strated that the P2X1-evoked component of SIPA was
dependent on calmodulin and MLCK activation. However,
ERK2 phosphorylation was primarily coupled directly to
GPIb and not P2X1, consequently, the reduction in SIPA
observed with U0126 was independent of P2X1 contribu-
tions [59]. Furthermore, shear-induced dense granule secre-
tion and aggregation were independent of all of the known
conventional, novel and atypical PKC isoforms [49].
Activation of P2X1 following secretion of ATP from
dense granules contributes to the Ca
2+ increase induced by
all major platelet agonists, including collagen, thrombin,
thromboxane A2 and ADP [29, 76]. Patch clamp studies in
the megakaryocyte show that autocrine activation of P2X1
occurs as a series of discrete events with a quantal
amplitude distribution, suggesting that granular ATP release
stimulates groups of P2X1 receptors in a multiple, focal
manner [111, 116, 117]. It has been suggested that this may
result from a close proximity of release sites to P2X1
receptors or be due to compartmentalization of ATP release
by the open canalicular system/demarcation membrane
system [111]. Either way, ATP release very efficiently
activates P2X1-dependent Ca
2+ influx [29]. The central role
of Ca
2+ in platelet activation is demonstrated by the ability of
cytosolic BAPTA (a Ca
2+ chelator) to block or markedly
inhibit a number of mainstream platelet responses, including
inside-out activation of αIIbβ3, procoagulant activity and
arachidonate production [118–120]. However, intracellular
Ca
2+ normally operates in tandem with other signalling
Purinergic Signalling (2011) 7:341–356 347pathways to synergistically stimulate functional events
[118–122], which probably explains the ability of P2X1
receptors to enhance aggregation mediated by a number of
other agonists, particularly collagen and thrombin (see
previous section).
Precisely howP2X1-dependent signals couple to inside-out
activation of αIIbβ3 alone, or during co-stimulation of other
platelet receptors, remains unclear. A major candidate is Ca
2+
and diacylglycerol (DAG)-regulated guanine nucleotide
exchange factor I (CalDAG-GEFI) [123]. CalDAG-GEFI is
an intracellular signalling molecule involved in the activation
of small GTPases of the Ras family [124]. It contains binding
sites for Ca
2+ and DAG and a guanine nucleotide exchange
factor (GEF) responsible for catalyzing the activation of Rap1
and Rap2. The expression of CalDAG-GEFI is restricted to
only a few cell types namely neurons, neutrophils and
platelets/megakaryocytes [124, 125]. Several studies on
platelets and other cell types have demonstrated only a very
weak affinity of the C1 domain for DAG suggesting that
CalDAG-GEFI is predominantly regulated by Ca
2+.F o r
example, studies performed in CalDAG-GEFI-deficient pla-
telets have demonstrated reduced activation of integrin
αIIbβ3,i na d d i t i o nt oi m p a i r e dg r a n u l er e l e a s ea n dr e d u c e d
TXA2 production [125–127]. Convulxin (100 ng/ml)-stimu-
lated TXB2 generation was completely abolished in CalDAG-
GEFI-deficient platelets and reduced in response to higher
convulxin concentrations (500 ng/ml); similarly, ERK phos-
phorylation and Rap1 activation were abolished in CalDAG-
GEFI-deficient platelets at low dose convulxin and delayed
and reduced at higher doses [126].
The signalling pathways and regulation of platelet P2X1
receptors is summarized in Fig. 2.
In vivo studies of platelet P2X1 receptor function
Genetic deletion or selective pharmacological inhibition of
P2X1 receptors in mice has only mild effects on haemo-
stasis, with most P2X1
−/− animals displaying no change in
tail bleed time [41, 71]. Furthermore, P2X1 receptor-
deficient mice have normal platelet counts, unaltered levels
of major adhesion receptors and normal megakaryocyte
development, indicating no major role for this ATP-gated
channel in platelet production [21, 71]. In contrast, in a
platelet-dependent model of acute vascular occlusion where
animals are challenged by co-injection of adrenaline and
collagen, loss of P2X1 receptors reduced thrombus forma-
tion and halved the number of mice that normally die as a
consequence of blocked pulmonary circulation [71]
(Fig. 3a). Furthermore, loss of P2X1 responses reduced
the size of a non-occlusive thrombus induced by laser
injury of small arteries or arterioles in both cremaster
muscle and mesentery [40, 71] (Fig. 3b). Whilst the role for
P2X1 receptors in thrombus development in mesenteric
arteries has been attributed to its interaction with exposed
collagen combined with the effect of high shear, synergistic
interactions with PAR receptors were suggested to account
for the effect in cremaster muscle. The suggested role for
thrombin:P2X1 interactions in the latter study is based upon
the view that laser-induced thrombus formation in cremaster
muscle is largely thrombin-dependent [128], combined with
the observation that P2X1 deletion had no effect in another
thrombosis model suggested to be GPVI/collagen-dependent
(occlusive thrombus formation following injury of carotid
arteries with FeCl3)[ 129]. More work is required to clarify
the underlying mechanisms of P2X1 involvement, which
could vary depending upon the vascular bed, the extent of
damage, or the stimulus (chemical versus laser) [129, 130].
Nevertheless, P2X1 clearly represents a potentially important
target for antithrombotic therapy, as shown by treating mice
with low concentrations of NF449 [41, 59]. Greater
antithrombotic effects are observed with P2X1 blockers in
arteriolar compared to venular models of localised thrombo-
sis [59], which is consistent with an increased contribution of
this cation channel to platelet adhesion as the shear level
increases [49, 71, 75]. In addition, low levels of NF449
significantly reduced the levels of systemic thrombosis
resulting from co-injection of collagen and adrenaline [41],
as predicted from the ability of P2X1 to enhance collagen-
induced aggregation in vitro [43, 71], although the role of
shear stress in this model is unclear. Importantly, as shown in
one comparative study of P2X1
−/−,P 2 Y 1
−/− and P2Y12
−/−
mice [40], the reduction in thrombus area following loss of
P2X1 (reduction to ≈23% of control) [40] was as large as
that observed following loss of either P2Y1 or P2Y12
(Fig. 3b (ii)). Thus, considering the lower risk of bleeding
[41, 71, 83, 84, 131], therapeutic targeting of P2X1 receptors
may have greater advantages compared to P2Y1 or P2Y12.
Transgenic mice over-expressing human P2X1 receptors in
their platelets show enhanced thrombosis in intestinal
arterioles induced by release of reactive oxygen species
from the photosensitive dye Rose Bengal, and also acceler-
ated death following intravenous injection of collagen and
adrenaline [59, 75]. This murine model raises the possibility
that increased platelet P2X1 receptor responses could elevate
the risk of thrombosis, although no disease phenotype has
yet been shown to enhance P2X1 expression. Interestingly,
one study has reported far greater P2X1-evoked shape
change responses in human compared to murine platelets
ex vivo [40]. It is possible that this reflects greater levels of
desensitisation during platelet separation, as higher relative
centrifugal forces are often used to prepare mouse platelets.
However, an alternative explanation is that human platelets
possess a higher density of P2X1 receptors, which could
translate into greater antithrombotic benefits of blocking this
receptor compared to those reported in murine studies.
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activation have used relatively young animals and yet
atherosclerosis is a disease that develops with age. Consid-
ering that collagen is a component of atherosclerotic plaques
and shear is considerably enhanced at sites of stenosis caused
by atheromas [132–134], P2X1 may play more crucial roles
in acute thrombotic events following plaque rupture than
suggested from the thrombosis models used so far.
How are platelet P2X1 receptors stimulated
and modulated in the circulation?
To date, P2X1 receptor activation has only clearly been
demonstrated following exposure to an extracellularly
applied ligand. Thus, no study has reported a constitutively
active P2X1 mutant, as shown for certain GPCRs, although
this has been observed for a mutant of the non-desensitising
P2X2 receptor [135, 136]. There is also no current evidence
to suggest that the P2X1 receptor is directly mechanosensi-
tive, thus the greater contribution of P2X1 receptors in the
arterial circulation or under high shear may result from the
relatively greater speed of activation of P2X1 compared to
other platelet Ca
2+ elevating receptors, or reflect shear-
dependent secondary activation of P2X1 by ATP released
from endothelial cells, platelets or other blood cells. ATP is
present at millimolar concentrations in the cell cytoplasm,
thus vascular damage leads to rapid and sustained intravas-
cular concentrations of this nucleotide [137]. ATP is also
stored at ≈0.5 M in the platelet dense granules and will reach
concentrations at the platelet surface membrane well in
excess of the level needed to activate P2X1 receptors [138].
Indeed, P2X1 is efficiently activated at very low concen-
trations of some agonists, particularly collagen, and the
levels of ATP measured in the bulk phase suggest that P2X1
receptors are mainly activated in an autocrine as opposed to
paracrine manner [29]. Red blood cells release significant
amounts of ATP in response to hypoxia and shear stress
[139, 140], which may also activate platelet P2X1 receptors.
As described in the “Introduction” section, ATP is unable to
stimulate functional responses through platelet P2Y1 and
P2Y12 receptors due to their low level of expression [1–6].
Consequently, ATP can act as a competitive antagonist of
ADP-evoked platelet responses [66, 141, 142]. It is therefore
interesting to speculate that this effect may increase the
relative importance of P2X1 compared to P2Y receptors in
platelet activation prior to conversion of released ATP to
ADP by nucleotidases.
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Fig. 2 P2X1 receptor signalling and regulation in the platelet. Summary of the pathways whereby P2X1 receptors have been proposed to couple to
functional responses in platelets, together with the mechanisms that regulate these ion channels. See text for explanationOther than ATP, P2X1 receptors are also stimulated by
several related compounds that have been shown to be
released into the bloodstream. These include a number of
diadenosine polyphosphates (ApnAs) and adenosine poly-
phosphoguanosines (ApnGs) [44, 143–148] that are stored
and secreted from platelet dense granules. Of these
compounds, Ap4A and Ap5A have received most attention
as they are stored at the highest concentrations, although at
levels many fold lower than ATP [149–151]. Furthermore,
most ApnAs and ApnGs active at P2X1 receptors in rat
mesenteric arteries are partial agonists and 10-fold-less
potent than α,β-meATP or ATP [146, 152]. Since
diadenosine polyphosphates are less rapidly degraded
compared to ATP [153, 154], they may act as longer
range P2X1 receptor stimuli. Uridine adenosine tetraphos-
phate (Up4A) and adenosine tetraphosphate (Ap4)a r e
released from endothelial cells in response to agonists or
mechanical shear and reach plasma concentrations that
induce potent P2X1-dependent vasoconstriction in a rat
perfused kidney model [155, 156]. Indeed, Ap4 is the most
a
b (i)
(ii)
Fig. 3 In vivo evidence for a
contribution of platelet P2X1
receptors to thromboembolism
and thrombosis. a Improved
survival of P2X1-deficient mice
following collagen/adrenaline
injection due to reduced
pulmonary thromboembolism.
b Laser-induced thrombus de-
velopment in murine cremaster
muscle arterioles; (i) images
showing the deposition of
fluorescently tagged platelets in
wild-type (WT) and P2X1
−/−
mice following laser injury at
the position marked by the
arrow head; L indicates the
arteriole lumen and the arrow
shows the direction of blood
flow (ii). Comparison of
thrombus area development
in WT, P2X1
−/−, P2Y1
−/− and
P2Y12
−/−. Reproduced from
references [40, 71], with
permission
350 Purinergic Signalling (2011) 7:341–356potent endothelial-derived vasoconstrictor reported to date
u s i n gt h i sa s s a y .M o r ew o r ki sr e q u i r e dt oc o n f i r mt h et r u e
potency of these various compounds compared to ATP on
platelet P2X1 receptors. One study reports an EC50 of
0.1 μMf o rA p 4A at platelet P2X1 receptors [157],
however this is much lower than concentrations reported
previously to be effective for this receptor in human
platelets (EC50 23.5 μM) [44, 111] or rat mesenteric
smooth muscle (no maximal response, but ≈50 μM
required for 50% of the response to 10 μM αβ-meATP
[146]). Although earlier data suggested that ADP is a
weak agonist of wild-type P2X1 receptors [28, 31, 91, 92,
147] or a preferential agonist at a naturally occurring
shortened variant [158], it is now firmly established that
ADP has no agonist activity at native or recombinant
P2X1 receptors [64, 94].
Another important feature of platelet P2X1 receptors is
their resistance to inhibition by cyclic nucleotides [91, 111,
159–161]. Thus, the major endothelial-derived platelet
inhibitors, prostacyclin and nitric oxide, which inhibit IP3-
dependent Ca
2+ mobilisation in platelets, will have little or
no effect on Ca
2+ influx through P2X1 receptors. Therefore,
P2X1 could be active under conditions where other Ca
2+
mobilisation pathways are normally totally suppressed, and
thus represent a particularly important early signal in the
cascade of reactions leading to thrombus development.
Conclusions
A wealth of studies have shown that P2X1 receptors can
enhance platelet activation by a variety of agonists and
contribute to thrombus development in a number of
murine models. These rapidly gated non-selective cation
channels are the only platelet receptor to be activated by
ATP released from blood cells or from damaged vascular
cells. Furthermore, unlike IP3 receptor-dependent Ca
2+-
mobilisation, they are not inhibited by increased cytosolic
cyclic nucleotides and thus are resistant to the main
mechanism whereby platelet activation is controlled in the
intact circulation. Consequently, pharmacological block of
P2X1 receptors may provide novel therapeutic outcomes,
particularly when one considers that platelets have
proposed roles in the aetiology of cancer, atherogenesis
and asthma, in addition to their recognised major
precipitating role in arterial thrombosis.
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